As the COVID-19 pandemic continues, conversations regarding vaccine price, access, and healthcare equity are being held around the world. One proposed solution to these continued vaccine and healthcare questions includes the use of a health technology assessment (HTA). Such an organization would use cost-effectiveness analyses to determine the price of COVID-19 therapeutics.
“The COVID-19 pandemic underscores pressures between balancing affordability, access, value, and ethics of healthcare technologies and other services. Policy makers have an obligation to ensure efficient use of resources and aligning price with the value. HTAs and national health services have an important role in evaluating the costs associated with different vaccines (eg, costs per dose and implementation costs), identifying barriers to efficient manufacturing and distribution, assisting with monitoring long-term safety and efficacy, and helping to determine the most ideal and cost-effective vaccination strategy from both societal and healthcare points of view.” Read more here.
(Source: Allie Choate, Xcenda, 5/13/21)